Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Raven biotechnologies has completed enrollment of patients in the maximum tolerated dose cohort expansion segment of its Phase I/IIa trial of RAV12 for the treatment of adenocarcinomas.
Subscribe to our email newsletter
All patients in the trial have undergone radiographic re-evaluation to assess their response to treatment. Based on this assessment, two patients remain on study drug beyond the original treatment period. A total of four patients received extended therapy in both the original cohort and the expanded cohort of this trial.
The appropriate dose and schedule of RAV12 previously was chosen in a dose-escalation segment of the Phase I/IIa trial that involved 33 patients. This trial revealed that a fractionated dosing regimen provided an improved side effect profile for the antibody. The recently concluded maximum tolerated dose (MTD) Cohort Expansion segment involved 20 additional patients.